The size of the Neisseriaceae Infections market in Europe is projected to grow at a robust CAGR from 2023 to 2028. The market growth in Europe can be attributed to favorable regulatory rules and greater use of recycled medical devices in the healthcare industry. Furthermore, lower prices and higher quality of recycled medical equipment are other factors propelling the industry forward. The market is likely to increase steadily from 2016 to 2020 due to the rising prevalence of Neisseriaceae infections and continual R&D operations in Europe.
Increased screening and the development of more sensitive and precise screening technologies like Nucleic Acid Amplification (NAAT) Tests are likely to blame for the rise in Neisseria gonorrhea infections. Despite this, the increased prevalence of gonorrhea and the advent of novel diagnostic technologies are expected to move the market for gonorrhea treatments forward. Bacteria are the most ubiquitous microorganisms present in the environment, and they play a critical role in the progression of any disease infection in people and animals.
In addition, the risk of gonorrhea has increased as the prevalence of homosexuality and bisexuality has increased. Expanding public awareness of infections and diseases, as well as rising medical expenses, enhance these variables. As a result of these factors, the market is expected to increase steadily.
Although laboratory tests are exceedingly sensitive, their high prices and technical constraints make them impossible to use daily, limiting their impact on STI control and management. Moreover, people are becoming aware of the long-term implications of Neisseria gonorrhoeae infections. Furthermore, the increased prevalence of infectious diseases is a significant stumbling barrier to the market's advancement to the higher end. Obstacles like government austerity, high treatment and R&D expenditures, and a lack of awareness about the symptoms, on the other hand, may hinder the market's growth.
This research report on the Europe Neisseriaceae infections market has been segmented and sub-segmented into the following categories:
By Type of Bacteria:
By Disease:
By Antibacterial Drugs:
By Country:
Regionally, at present, Europe is the second most prominent market, owing to the growing prevalence of various Neisseriaceae infections and associated diseases. The majority of developed and developing countries in Europe have used all of their resources to bring the pandemic under control. As a result, in Germany and U.K, there has been an increase in the use of reprocessed medical equipment such as ventilators and cylinders, which is helping the reprocessed medical devices market generate revenue.
Furthermore, a huge number of drugs and formulations are likely to access the market between 2016 and 2020 due to extensive R&D procedures. The market for Neisseriaceae infections is one of the essential areas of the sector since it is based on the many bacteria in the class and diseases associated with them. Acinetobacter, Kingella, Neisseria, Moraxella, and Oligella are examples of bacteria.
According to the Centers for Disease Control and Prevention (CDC), Germany recorded more than 300,000 new cases of gonorrhea in 2012, up 4% from 2011. As a result, the rising prevalence of illnesses has become a critical component in regional market development.
KEY MARKET PLAYERS:
Companies playing a vital role in the European Neisseriaceae Infections market profiled in this report are Aphios Corporation, Basilea Pharmaceuticals Ltd., Pfizer, Inc., GSK plc, AstraZeneca plc, Adenium Biotech ApS, Dainippon Sumitomo Pharma Co., Ltd., Theravance, Inc., and Pfizer, Inc. amongst many others.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region